医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BeiGene to Present at the Guggenheim Healthcare Talks – 2022 Oncology Conference

2022年02月08日 PM08:00
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass. & BEIJING

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005585/en/

CONTACT

Investor

Kevin Mannix

+1 857-302-5189

ir@beigene.com

Media

Liza Heapes

+1 857-302-5663

media@beigene.com

同じカテゴリーの記事 

  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
  • Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
  • BrainChip Earns Australian Patent for Improved Spiking Neural Network
  • Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies